Galderma Group AG

Nemluvio (nemolizumab) now approved in Canada for atopic dermatitis and prurigo nodularis, offering a novel IL‑31RA blocker that cuts itch and inflammation in phase‑III trials.

Galderma’s strategy for the growing facial aesthetics market: a dual approach of diversified injectables, laser tech and strategic partnerships to navigate patent cliffs, competition and recalls while targeting high‑margin growth.

Explore how L’Oréal’s 20% stake in Galderma boosts injectable aesthetic returns, enhances supply‑chain resilience, and drives next‑generation dermatology growth.

Galderma Group AG’s modest share rise on 26 Nov shows strong biotech fundamentals, rising consumer confidence and a supportive SMI rally, highlighting its growth prospects and resilient pipeline.

Explore the global aesthetic fillers market, its 7.2 % CAGR, leading brands like Galderma, and evidence‑based safety and efficacy insights for clinicians and patients.

Galderma’s latest ASDS data show Restylane, Sculptra and Relfydess deliver strong, lasting volume with minimal side‑effects—evidence that could shape future aesthetic practice.

Galderma’s 2.6 billion‑CHF share sale fuels R&D, market expansion, and strategic M&A while keeping stock above the offer price, showcasing strong investor confidence and growth potential in dermatology and aesthetic medicine.

Galderma Group AG, a specialist in dermatological therapeutics, has reported a modest share price uptick, driven by solid fundamentals and a diversified pricing strategy, but faces patent expiration risks and must navigate market constraints to sust…

Galderma’s stock price is under scrutiny due to its high valuation and volatility, leaving investors wondering if it’s a sustainable price or a bubble waiting to burst.

Galderma’s share price has stabilized following the EQT sale, with a 52-week high of 138.8 CHF and a price to earnings ratio of 98.48, indicating potential for long-term growth.